- Home
- CTNM vs RCKT Comparison
CTNM vs RCKT Comparison
Compare CTNM & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- RCKT
- Stock Information
- Founded
- CTNM 2009
- RCKT 1999
- Country
- CTNM United States
- RCKT United States
- Employees
- CTNM N/A
- RCKT N/A
- Industry
- CTNM
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- RCKT Health Care
- Exchange
- CTNM Nasdaq
- RCKT Nasdaq
- Market Cap
- CTNM 328.1M
- RCKT 340.9M
- IPO Year
- CTNM 2024
- RCKT N/A
- Fundamental
- Price
- CTNM $10.93
- RCKT $2.96
- Analyst Decision
- CTNM Strong Buy
- RCKT Buy
- Analyst Count
- CTNM 5
- RCKT 14
- Target Price
- CTNM $20.40
- RCKT $29.12
- AVG Volume (30 Days)
- CTNM 166.5K
- RCKT 2.1M
- Earning Date
- CTNM 10-30-2025
- RCKT 11-06-2025
- Dividend Yield
- CTNM N/A
- RCKT N/A
- EPS Growth
- CTNM N/A
- RCKT N/A
- EPS
- CTNM N/A
- RCKT N/A
- Revenue
- CTNM N/A
- RCKT N/A
- Revenue This Year
- CTNM N/A
- RCKT N/A
- Revenue Next Year
- CTNM N/A
- RCKT $3,582.16
- P/E Ratio
- CTNM N/A
- RCKT N/A
- Revenue Growth
- CTNM N/A
- RCKT N/A
- 52 Week Low
- CTNM $3.35
- RCKT $2.19
- 52 Week High
- CTNM $16.25
- RCKT $15.01
- Technical
- Relative Strength Index (RSI)
- CTNM 47.95
- RCKT 37.45
- Support Level
- CTNM $10.46
- RCKT $2.85
- Resistance Level
- CTNM $13.09
- RCKT $3.07
- Average True Range (ATR)
- CTNM 0.98
- RCKT 0.18
- MACD
- CTNM 0.08
- RCKT -0.05
- Stochastic Oscillator
- CTNM 29.68
- RCKT 19.44
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.